Study finds early anti-VEGF treatment of diabetic retinopathy does not improve visual acuity

Raj Maturi, MD, is shown with a patient. Images illustrate vision improvement with treatment for diabetic retinopathy. (Image courtesy of Raj Maturi, MD)

In a clinical study from the DRCR Retina Network, early treatment of diabetes-related eye disease slowed progression to severe disease, but it did not improve visual acuity compared with treating more severe disease once it developed.

The study was funded by the National Eye Institute (NEI), part of the National Institutes of Health.

“This study indicates that monitoring patients regularly for vision-threatening diabetes complications and treating eyes only as needed is the best approach,” Raj Maturi, MD, Indiana University School of Medicine and Retina Partners Midwest, said in a NEI/NIH news release.

Maturi is the protocol chairman for the four-year study. The report was published in the Journal of the American Medical Association (JAMA).¹

According to the news release, anti-vascular endothelial growth factor (anti-VEGF) drugs can substantially decrease the risk of vision loss from diabetic retinopathy. However, eye care providers have been unsure when treatment should start to achieve the best long-term outcome. Anti-VEGF is given by injection into the eye, so physicians must weigh the risks for side effects and the expense and inconvenience of treatment against potential treatment benefit.

In early stages of diabetic retinopathy, diabetes weakens retinal blood vessels, causing fluid to leak into the surrounding retina. Diabetic macular edema, a key complication of diabetic retinopathy, can lead to vision loss. Progression of the disease to proliferative diabetic retinopathy (PDR), where new, abnormal blood vessels begin to grow in the retina, can also threaten vision.

According to the news release, NEI-funded researchers evaluated whether treating people with NPDR with the anti-VEGF drug Eylea (aflibercept) could prevent vision loss. The study enrolled 328 participants, with 399 study eyes (some participants had 2eyes that met criteria for enrollment in the study; others only had 1 study-eligible eye).

Preventive anti-VEGF injections were given in 200 eyes at 1 month after enrollment, 2months, and 4 months, and then every 4 months over 2 years. Preventative treatment continued every 4 months through 4 years unless NPDR improved to only mild disease. Sham injections (without drug) were used in 199 eyes over the same period. Any eye that developed a vision-threatening complication, such as macular edema or PDR was treated with additional anti-VEGF injections as necessary.

According to the NEI/NIH news release, the two-year results of the study demonstrated that while preventive treatment reduced the risk of developing diabetic macular edema or PDR, there was no evident benefit to vision. Moreover, the final 4-year results serve to reinforce earlier data, with no statistical difference in either visual acuity or rates of vision loss between the two groups.

“We expected early treatment to prevent progression of diabetic retinopathy, but even with preventative injections, about one-third of eyes developed vision-threatening complications,” Adam Glassman, Jaeb Center for Health Research, Tampa, Florida, said in the news release. He also directs the DRCR Retina Network coordinating center.

Over the 4-year study, 34% percent of eyes receiving preventive treatments showed disease progression, compared with 57% of those in the sham group. On average, those in the preventive group received 11 injections, compared with an average of 3 in the sham group.

“While the individual risk of complications per injection is low, the risk increases with each additional injection,” Jennifer Sun, MD, MPH, Joslin Diabetes Center, Harvard Medical School, Boston, and chair of diabetes initiatives for the DRCR Retina Network, said in the news release. “The results of this study indicate that the anatomic benefit from early anti-VEGF treatment does not result in improved visual acuity, and so it may not be worth the risk and inconvenience to the patient of repeat preventive injections for NPDR.”

According to the news release, the study was supported by NEI and the National Institute of Diabetes and Digestive and Kidney Diseases, with funding through the Special Diabetes Program, through a cooperative agreement (EY14231). Regeneron provided aflibercept for the study and funds to DRCR Retina Network to defray the study’s clinical site costs. JDRF also provided funds to defray clinical site costs.

Reference

1. Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had, H, Stockdale CR, and Sun JK, for the DRCR Retina Network. “Four-Year Visual Outcomes in a Randomized Trial of Intravitreous Aflibercept for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W).” JAMA. February 7, 2023.